ASX · AVE.AX
Avecho Biotechnology Limited
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
Loading market information…
ASX · TRP.AX · AUD
Stock price, earnings
Quote as of Oct 29, 2026, 02:54 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Tissue Repair Ltd’s quoted price sits in the lower half of its reported 52-week range, 80.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Tissue Repair Ltd’s next earnings report is currently expected on Mar 4, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Tissue Repair Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures. Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries. Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas. The company was founded in 2012 and operates from its headquarters in Sydney, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.01+A$0.00 (+7.69%)
Avecho Biotechnology Limited’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
A$0.07A$0.00 (0.0%)
Nanollose Limited’s quoted price sits in the upper half of its reported 52-week range, 10.84% below the high.
A$0.02A$0.00 (0.0%)
Neurotech International Limited’s quoted price sits in the upper half of its reported 52-week range, 19.05% below the high.
A$0.05A$0.00 (0.0%)
BTC Health Limited’s quoted price sits in the lower half of its reported 52-week range, 27.14% below the high.
A$0.02-A$0.00 (-4.76%)
Althea Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 44.44% below the high.
A$0.05A$0.00 (0.0%)
Noxopharm Limited’s quoted price sits in the lower half of its reported 52-week range, 55.45% below the high.
A$0.01-A$0.00 (-6.67%)
Atomo Diagnostics Limited’s quoted price sits in the lower half of its reported 52-week range, 70.83% below the high.
A$0.04A$0.00 (0.0%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 59.18% below the high.
